Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study

Table 3 Regression coefficients for group differences at follow up

Rating	Regression coeffiecient, B (95 % CI)	Beta-cofficient	SE	Z	P
Adjusted for pre-treatment rating scores
HTQ	0.07 (−0.09 – 0.22)	0.06	0.08	0.84	0.40
HSCL-25	0.07 (−0.10 – 0.23)	0.05	0.08	0.80	0.42
SCL	0.12 (−0.12 – 0.35)	0.07	0.12	1.03	0.31
SDS	2.31 (0.10 – 4.52)	0.16	1.13	2.05	0.04*
WHO-5	−5.79 (−12.05 – 0.46)	−0.13	3.19	−1.82	0.07*
VAS	0.36 (−0.23 – 0.96)	0.08	0.30	1.20	0.23
SAS-SR	0.10 (−0.09 – 0.29)	0.07	0.10	1.06	0.29
CSS	−0.35 (−2.18 - 1.47)	−0.02	0.93	−0.35	0.71
GAF-F	1.22 (−1.03 – 3.47)	0.08	1.15	1.07	0.29
GAF-S	0.06 (−2.37 – 2.48)	0.00	1.24	0.04	0.96
HAM-D	0.19 (−1.94 – 2.33)	0.01	1.09	0.18	0.86
HAM-A	−0.57 (−3.19 – 2.04)	−0.03	1.34	−0.43	0.67

Post-treatment differences between the venlafaxine and sertraline groups for the intention-to-treat sample
CSS Crisis Support Scale, GAF Global Assessment of Functioning, HAM-A Hamilton Anxiety scale, HAM-D Hamilton Depression scale, HTQ Harvard Trauma Questionnaire, HSCL-25 Hopkins Symptom Checklist-25, SAS-SR Social Adjustment Scale - Self Report, SCL-90 Symptom Checklist-90, SDS Sheehan Disability scale, VAS Visual Analogue Scale, WHO-5 WHO-Five Well-being Index, B Regression coeffiecient, CI Confidence interval, Z Z-value SE Robust standard error of the regression coeffiecient, B, P P-value for the regression coeffiecient, B
Bold: In favor of sertraline
Italic: In favor of venlafaxine
Bold and *: Statistically significant
*: Marginally significant

ISSN: 1471-244X